Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Dexamethasone

FDA-approved product (tablet, oral), marketed as Aeroseb-Dex, Decaderm, Decadron and 13 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Dexamethasone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Adrenal gland disease
  • Adrenal gland hyperfunction
  • Allergic conjunctivitis
  • Allergic rhinitis
  • Ankylosing spondylitis
  • Aplastic anemia
  • Asthma
  • Atopic eczema
  • Autoimmune thrombocytopenic purpura
  • Bursitis
  • Cancer
  • Chorioretinitis
  • Choroiditis
  • Classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency
  • Congenital adrenal hyperplasia
  • and 62 more

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids for local oral treatment; Corticosteroids; Corticosteroids, moderately potent (group ii); Corticosteroids, moderately potent, other combinations; Corticosteroids, combinations for treatment of acne
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA53.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli32.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae30.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Dexamethasone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Dexamethasone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

    NCT00250718 · start 2004-10

    Registered record
    Registry ID
    NCT00250718
    Conditions
    Non-Hodgkin's Lymphoma; Cancer
    Interventions
    Vincristine; VP-16; Rituximab; Dexamethasone; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2004-10
    Completion
    2014-05
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Hodgkin's Lymphoma; Cancer
    InterventionVincristine; VP-16; Rituximab; Dexamethasone +1 more
    PhasePhase 2
    Registry statusTerminated

  • R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

    NCT00137995 · start 2003-06

    Registered record
    Registry ID
    NCT00137995
    Conditions
    Lymphoma, Large-Cell, Diffuse
    Interventions
    Rituximab; Etoposide; Carboplatine; Ifosfamide + Mesna; Cisplatine; Cytosine Arabinoside; Dexamethasone; Autologous Stem Cell Transplantation; BCNU; Etoposide; Cytarabine; Melphalan
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-06
    Completion
    2008-10
    Enrolment
    481

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, Large-Cell, Diffuse
    InterventionRituximab; Etoposide; Carboplatine; Ifosfamide + Mesna +8 more
    PhasePhase 3
    Registry statusCompleted

  • Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

    NCT00130195 · start 2002-09

    Registered record
    Registry ID
    NCT00130195
    Conditions
    Acute Lymphoblastic Leukemia
    Interventions
    imatinib; cyclophosphamide; daunorubicin; vincristine; prednisolone; methotrexate; cytarabine; dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-09
    Completion
    2008-05
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia
    Interventionimatinib; cyclophosphamide; daunorubicin; vincristine +4 more
    PhasePhase 2
    Registry statusCompleted

  • Dexamethasone Treatment for Congenital Heart Block (CHB) in Newborns With Lupus

    NCT00007358 · start 2000-10

    Registered record
    Registry ID
    NCT00007358
    Conditions
    Congenital Heart Block; Neonatal Lupus; Atrioventricular Nodal Dysfunction; Myocardial Injury
    Interventions
    Dexamethasone or other corticosteroid
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2000-10
    Completion
    2008-10
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Heart Block; Neonatal Lupus; Atrioventricular Nodal Dysfunction; Myocardial Injury
    InterventionDexamethasone or other corticosteroid
    PhaseNot applicable
    Registry statusCompleted

  • High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

    NCT00002788 · start 1995-10

    Registered record
    Registry ID
    NCT00002788
    Conditions
    Leukemia
    Interventions
    filgrastim; cyclophosphamide; dexamethasone; etoposide; peripheral blood stem cell transplantation; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1995-10
    Completion
    2002-09
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    Interventionfilgrastim; cyclophosphamide; dexamethasone; etoposide +2 more
    PhasePhase 1
    Registry statusCompleted